Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Baselga, José Im, Seock-Ah Iwata, Hiroji Cortés, Javier De Laurentiis, Michele Jiang, Zefei Arteaga, Carlos L Jonat, Walter Clemons, Mark Ito, Yoshinori Awada, Ahmad Chia, Stephen Jagiełło-Gruszfeld, Agnieszka Pistilli, Barbara Tseng, Ling-Ming Hurvitz, Sara Masuda, Norikazu Takahashi, Masato Vuylsteke, Peter Hachemi, Soulef Dharan, Bharani Di Tomaso, Emmanuelle Urban, Patrick Massacesi, Cristian Campone, Mario